Trials / Completed
CompletedNCT04612374
Exploring the Acceptability and Efficacy of a Transdiagnostic Treatment for Misophonia
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Despite increasing recognition of misophonia, there are currently no evidence-based treatments to help those who are suffering. Therefore, the primary purpose of this study is to assess the acceptability, feasibility, and preliminary efficacy of a treatment for misophonia. This study will be conducted in two phases. In the Phase 1, participants will receive a treatment the investigators believe can help manage symptoms of misophonia: The Unified Protocol. This treatment uses evidence-based psychological principles (e.g., managing attention or behavior) in a flexible manner and will focus on developing skills to help reduce the distress and impairment associated with Misophonia. After treatment, patients will provide feedback about their experience. The investigators will use this feedback to revise the treatment as indicated. In Phase 2, participants will receive the revised treatment and provide feedback on their experience. Throughout treatment in either phase, participants will provide daily and weekly information about their symptoms. The aims of this study are (1) to explore the acceptability and feasibility of the Unified Protocol for individuals who experience Misophonia and (2) to examine whether this treatment helps reduce symptoms associated with Misophonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Unified Protocol for Transdiagnostic Treatment of Emotional Disorders | Please see arm/group descriptions |
| BEHAVIORAL | Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders | Please see arm/group descriptions |
Timeline
- Start date
- 2020-12-21
- Primary completion
- 2022-08-04
- Completion
- 2022-08-04
- First posted
- 2020-11-03
- Last updated
- 2022-08-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04612374. Inclusion in this directory is not an endorsement.